Results 161 to 170 of about 300,077 (226)
Some of the next articles are maybe not open access.
Hematology/Oncology Clinics of North America, 2003
The differential diagnosis of an elevated hematocrit and the criteria for the diagnosis of polycythemia vera present little or no problem; however, there is not a consensus on therapy. Spivak likened this to a conundrum--"an intricate and difficult problem." Nonetheless, it can be argued that on the basis of the following criteria--life expectancy, the
Nathanial, Berlin, Nathanial I, Berlin
+7 more sources
The differential diagnosis of an elevated hematocrit and the criteria for the diagnosis of polycythemia vera present little or no problem; however, there is not a consensus on therapy. Spivak likened this to a conundrum--"an intricate and difficult problem." Nonetheless, it can be argued that on the basis of the following criteria--life expectancy, the
Nathanial, Berlin, Nathanial I, Berlin
+7 more sources
Current Treatment Options in Oncology, 2018
Polycythemia vera (PV) is the most common myeloproliferative neoplasm (MPN), the ultimate phenotype of the JAK2 V1617F mutation, the MPN with the highest incidence of thromboembolic complications, which usually occur early in the course of the disease, and the only MPN in which erythrocytosis occurs. The classical presentation of PV is characterized by
Andrea Girnius, Lesley Gilbertson
+5 more sources
Polycythemia vera (PV) is the most common myeloproliferative neoplasm (MPN), the ultimate phenotype of the JAK2 V1617F mutation, the MPN with the highest incidence of thromboembolic complications, which usually occur early in the course of the disease, and the only MPN in which erythrocytosis occurs. The classical presentation of PV is characterized by
Andrea Girnius, Lesley Gilbertson
+5 more sources
Hepcidin Mimetics in Polycythemia Vera: Resolving the Irony of Iron deficiency and Erythrocytosis
Current opinion in hematology, 2022Purpose of review Development of hepcidin therapeutics has been a ground-breaking discovery in restoring iron homeostasis in several haematological disorders.
S. Handa +3 more
semanticscholar +1 more source
Internal and Emergency Medicine, 2010
The diagnostic approach to a patient with polycythemia has been greatly simplified by the introduction of new genetic testing in addition to traditional tests, such as measurement of red cell mass and serum erythropoietin (Epo) level. Clonal erythrocytosis, which is the diagnostic feature of polycythemia vera (PV), is almost always associated with a ...
Raffaele, Landolfi +3 more
openaire +2 more sources
The diagnostic approach to a patient with polycythemia has been greatly simplified by the introduction of new genetic testing in addition to traditional tests, such as measurement of red cell mass and serum erythropoietin (Epo) level. Clonal erythrocytosis, which is the diagnostic feature of polycythemia vera (PV), is almost always associated with a ...
Raffaele, Landolfi +3 more
openaire +2 more sources
Annals of Internal Medicine, 1964
Excerpt It is generally considered that the demonstration of arterial oxygen unsaturation in a patient with polycythemia indicates a secondary rather than a primary cause for the increase in red ce...
M, LERTZMAN +3 more
openaire +2 more sources
Excerpt It is generally considered that the demonstration of arterial oxygen unsaturation in a patient with polycythemia indicates a secondary rather than a primary cause for the increase in red ce...
M, LERTZMAN +3 more
openaire +2 more sources
Chemotherapy in Polycythemia Vera
Acta geneticae medicae et gemellologiae, 1968Summary210 cases of polycythemia vera were observed over a period of 15 years. The majority of them received P32; treatment with Myleran instead of with radioactive phosphorus was instituted only recently. To a small number of patients chemotherapy was given alternately with P32.
G, Stecher, G, Reinhardt
openaire +2 more sources
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
New England Journal of MedicineBACKGROUND Polycythemia vera is a chronic myeloproliferative neoplasm characterized by erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory hormone hepcidin, restricts the availability of iron for erythropoiesis.
M. Kremyanskaya +18 more
semanticscholar +1 more source
New England Journal of Medicine, 1963
THE course of polycythemia vera is complicated by hemorrhagic and thromboembolic phenomena of varying severity occurring in about a third of the cases. These complications have been ascribed to the hypervolemia and increased red-cell mass, with resultant sluggish blood flow, capillary distention with poor retractability, thrombocytosis and a complex ...
L R, WASSERMAN, H S, GILBERT
openaire +2 more sources
THE course of polycythemia vera is complicated by hemorrhagic and thromboembolic phenomena of varying severity occurring in about a third of the cases. These complications have been ascribed to the hypervolemia and increased red-cell mass, with resultant sluggish blood flow, capillary distention with poor retractability, thrombocytosis and a complex ...
L R, WASSERMAN, H S, GILBERT
openaire +2 more sources
Diagnosis and Treatment of Polycythemia Vera: A Review.
Journal of the American Medical Association (JAMA)Importance Polycythemia vera (PV), a myeloproliferative neoplasm characterized by an increased red blood cell mass and increased risk of thrombosis, affects approximately 65 000 people in the US, with an annual incidence of 0.5 to 4.0 cases per 100 000 ...
D. Tremblay +3 more
semanticscholar +1 more source
Cancer Cell, 2005
Polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibrosis (MMM) are clonal disorders arising from hematopoietic progenitors.
R. Levine +28 more
semanticscholar +1 more source
Polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibrosis (MMM) are clonal disorders arising from hematopoietic progenitors.
R. Levine +28 more
semanticscholar +1 more source